These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3774317)

  • 1. [A survey of debrisoquin hydroxylation polymorphism].
    Gachályi B; Róna K; Vas A; Káldor A
    Orv Hetil; 1986 Sep; 127(38):2299-301. PubMed ID: 3774317
    [No Abstract]   [Full Text] [Related]  

  • 2. Polymorphic 4-hydroxylation of debrisoquine in chronic discoid psoriasis.
    Chapman PH; Rawlins MD; Shuster S; Idle JR; Ritchie JC; Smith RL
    Eur J Clin Pharmacol; 1981; 21(3):257-8. PubMed ID: 6895622
    [No Abstract]   [Full Text] [Related]  

  • 3. Stereoselective 4-hydroxylation of debrisoquine in Nigerians.
    Lennard MS; Tucker GT; Woods HF; Iyun AO; Eichelbaum M
    Biochem Pharmacol; 1988 Jan; 37(1):97-8. PubMed ID: 3337737
    [No Abstract]   [Full Text] [Related]  

  • 4. Lack of defect in oxidative hydroxylation of debrisoquine in a patient with halothane hepatitis.
    Toutoungi M; Magnenat D
    Eur J Clin Pharmacol; 1990; 38(6):633-4. PubMed ID: 2373140
    [No Abstract]   [Full Text] [Related]  

  • 5. Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians.
    Woolhouse NM; Andoh B; Mahgoub A; Sloan TP; Idle JR; Smith RL
    Clin Pharmacol Ther; 1979 Nov; 26(5):584-91. PubMed ID: 498701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmocogenetic implications of polymorphic debrisoquine hydroxylations.
    Rawlins MD
    Q J Med; 1985 Feb; 54(214):115-6. PubMed ID: 3983355
    [No Abstract]   [Full Text] [Related]  

  • 7. Polymorphism of debrisoquine hydroxylation among Finns and Lapps.
    Arvela P; Kirjarinta M; Kirjarinta M; Kärki N; Pelkonen O
    Br J Clin Pharmacol; 1988 Nov; 26(5):601-3. PubMed ID: 3207564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug hydroxylator phenotype in Hungary.
    Szórády I; Sánta A
    Eur J Clin Pharmacol; 1987; 32(3):325. PubMed ID: 3595707
    [No Abstract]   [Full Text] [Related]  

  • 9. Lack of congruence of S-carboxymethyl-L-cysteine sulphoxidation and debrisoquine 4-hydroxylation in a Caucasian population.
    Haley CS; Waring RH; Mitchell SC; Shah RR; Idle JR; Smith RL
    Xenobiotica; 1985 May; 15(5):445-50. PubMed ID: 4036168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.
    Bertilsson L; Henthorn TK; Sanz E; Tybring G; Säwe J; Villén T
    Clin Pharmacol Ther; 1989 Apr; 45(4):348-55. PubMed ID: 2495208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Debrisoquine hydroxylation phenotyping: do we expect too much?
    Mitchell SC; Haley CS
    Lancet; 1990 Sep; 336(8716):694. PubMed ID: 1975883
    [No Abstract]   [Full Text] [Related]  

  • 12. Methoxyphenamine and dextromethorphan as safe probes for debrisoquine hydroxylation polymorphism.
    Roy SD; Hawes EM; Hubbard JW; McKay G; Midha KK
    Lancet; 1984 Dec; 2(8416):1393. PubMed ID: 6150386
    [No Abstract]   [Full Text] [Related]  

  • 13. Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype.
    Spina E; Steiner E; Ericsson O; Sjöqvist F
    Clin Pharmacol Ther; 1987 Mar; 41(3):314-9. PubMed ID: 3816019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variants of human microsomal enzymes.
    Davies DS; Boobis AR
    Biochem Soc Trans; 1983 Aug; 11(4):459-60. PubMed ID: 6617977
    [No Abstract]   [Full Text] [Related]  

  • 15. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
    Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
    J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings.
    Dahl-Puustinen ML; Lidén A; Alm C; Nordin C; Bertilsson L
    Clin Pharmacol Ther; 1989 Jul; 46(1):78-81. PubMed ID: 2743709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics. Enigmatic variations.
    Idle J
    Nature; 1988 Feb; 331(6155):391-2. PubMed ID: 3340186
    [No Abstract]   [Full Text] [Related]  

  • 18. Relationship between uptake and elimination of toluene and debrisoquin hydroxylation polymorphism.
    Löf A; Hansen SH; Näslund P; Steiner E; Wallén M; Hjelm EW
    Clin Pharmacol Ther; 1990 Mar; 47(3):412-7. PubMed ID: 2311341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Debrisoquine hydroxylation polymorphism and personality.
    Bertilsson L; Alm C; De Las Carreras C; Widen J; Edman G; Schalling D
    Lancet; 1989 Mar; 1(8637):555. PubMed ID: 2564084
    [No Abstract]   [Full Text] [Related]  

  • 20. Smoking, cancer, and Parkinson's disease.
    Golbe LI; Bernholc AA; Duvoisin RC
    Ann Neurol; 1987 May; 21(5):513. PubMed ID: 3592644
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.